skip to main content
Idioma:
Resultados 1 2 3 4 next page
Refinado por: Nome da Publicação: Annals Of Oncology remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Influence of FASL and FAS polymorphisms, enrolled in extrinsic apoptosis pathway, in the inherited increased risk of head and neck squamous cell carcinoma
Influence of FASL and FAS polymorphisms, enrolled in extrinsic apoptosis pathway, in the inherited increased risk of head and neck squamous cell carcinoma
Material Type:
Artigo 		Adicionar ao Meu Espaço

Influence of FASL and FAS polymorphisms, enrolled in extrinsic apoptosis pathway, in the inherited increased risk of head and neck squamous cell carcinoma

Lima, C.S.P. ; Liutti, V.T. ; Lima, T.R.P. ; Costa, E.F.D. ; Lopes-Aguiar, L. ; Nogueira, G.A.S. ; Leal, F. ; Santos, V.C.A. ; Oliveira, C.B.M. ; Rinck-Junior, J.A. ; Lourenço, G.J.

Annals of oncology, 2016-10, Vol.27, p.vi344-vi344 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível

Citações Citado por
2
Quality of life in newly diagnosed patients with cervical cancer in Brazil: Results of EVITA study (EVA/LACOG 0215)
Quality of life in newly diagnosed patients with cervical cancer in Brazil: Results of EVITA study (EVA/LACOG 0215)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Quality of life in newly diagnosed patients with cervical cancer in Brazil: Results of EVITA study (EVA/LACOG 0215)

Nogueira-Rodrigues, A. ; de Melo, A.C. ; Calabrich, A.F.D.C. ; Cronenberger, E. ; Torres, K.L. ; Damian, F. ; Cossetti, R. ; De Azevedo, C.R.A.S. ; da Fonseca, A.J. ; Nerón, Y. ; Nunes, J.S. ; Lopes, A. ; Thomé, F. ; Leal, R. ; Borges, G. ; Nunes Filho, P.R.S. ; Zaffaroni Caorsi, F. ; Freitas, R.D.S. ; Werutsky, G. ; Maluf, F.C.

Annals of oncology, 2018-10, Vol.29, p.viii349-viii349 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
3
Genetic signatures always suggest undertreatment? Experience with PAM50
Genetic signatures always suggest undertreatment? Experience with PAM50
Material Type:
Artigo 		Adicionar ao Meu Espaço

Genetic signatures always suggest undertreatment? Experience with PAM50

Sales, C. ; Vieira, I. ; Cassiano, M. ; Oliveira, C. ; Vieira, C. ; Ferreira, M. ; Rodrigues, A. ; Ferreira, A. ; Pousa, M.I. ; Couto, R. ; Leal, C. ; Abreu, J. ; Teixeira, M. ; Pereira, D. ; Sousa, S. ; Abreu, M.H.

Annals of oncology, 2018-10, Vol.29, p.viii69-viii69 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
4
Intracranial activity of ensartinib in patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC)
Intracranial activity of ensartinib in patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Intracranial activity of ensartinib in patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC)

Wakelee, H. ; Reckamp, K.L. ; Leal, T.A. ; Patel, S.P. ; Blumenschein, G. ; Shum, E. ; Nieva, J. ; Oxnard, G. ; Sanborn, R.E. ; Waqar, S. ; Zeman, K. ; Dukart, G. ; Harrow, K. ; Liang, C. ; Holzhausen, A. ; Horn, L.

Annals of oncology, 2018-10, Vol.29, p.viii541-viii542 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
5
Stage 2 enrollment complete: Sitravatinib in combination with nivolumab in NSCLC patients progressing on prior checkpoint inhibitor therapy
Stage 2 enrollment complete: Sitravatinib in combination with nivolumab in NSCLC patients progressing on prior checkpoint inhibitor therapy
Material Type:
Artigo 		Adicionar ao Meu Espaço

Stage 2 enrollment complete: Sitravatinib in combination with nivolumab in NSCLC patients progressing on prior checkpoint inhibitor therapy

Leal, T.A. ; Spira, A.I. ; Blakely, C. ; He, K. ; Berz, D. ; Richards, D. ; Uyeki, J. ; Savage, A. ; Roque, T. ; Massarelli, E. ; Jotte, R.M. ; Chen, I. ; Christensen, J. ; Olson, P. ; Tassell, V. ; Horn, L.

Annals of oncology, 2018-10, Vol.29, p.viii400-viii401 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
6
Primary efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC)
Primary efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Primary efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC)

Kim, E.S. ; Velcheti, V. ; Mekhail, T. ; Leal, T.A. ; Dowell, J.E. ; Tsai, M.L. ; Dakhil, C.S.R. ; Stella, P. ; Shen, V. ; Hu, S. ; Paul, S.M. ; Shames, D.S. ; Schleifman, E. ; Fabrizio, D.A. ; Yun, C. ; Phan, S. ; Socinski, M.A.

Annals of oncology, 2018-10, Vol.29, p.viii744-viii744 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
7
215PGenetic signatures always suggest undertreatment? Experience with PAM50
215PGenetic signatures always suggest undertreatment? Experience with PAM50
Material Type:
Artigo 		Adicionar ao Meu Espaço

215PGenetic signatures always suggest undertreatment? Experience with PAM50

Sales, C ; Vieira, I ; Cassiano, M ; Oliveira, C ; Vieira, C ; Ferreira, M ; Rodrigues, A ; Ferreira, A ; Pousa, M I ; Couto, R ; Leal, C ; Abreu, J ; Teixeira, M ; Pereira, D ; Sousa, S ; Abreu, M H

Annals of oncology, 2018-10, Vol.29 (suppl_8) [Periódico revisado por pares]

Oxford University Press

Texto completo disponível

Citações Citado por
8
978PQuality of life in newly diagnosed patients with cervical cancer in Brazil: Results of EVITA study (EVA/LACOG 0215)
978PQuality of life in newly diagnosed patients with cervical cancer in Brazil: Results of EVITA study (EVA/LACOG 0215)
Material Type:
Artigo 		Adicionar ao Meu Espaço

978PQuality of life in newly diagnosed patients with cervical cancer in Brazil: Results of EVITA study (EVA/LACOG 0215)

Nogueira-Rodrigues, A ; de Melo, A C ; Calabrich, A F D C ; Cronenberger, E ; Torres, K L ; Damian, F ; Cossetti, R ; De Azevedo, C R A S ; da Fonseca, A J ; Nerón, Y ; Nunes, J S ; Lopes, A ; Thomé, F ; Leal, R ; Borges, G ; Nunes Filho, P R S ; Zaffaroni Caorsi, F ; Freitas, R D S ; Werutsky, G ; Maluf, F C

Annals of oncology, 2018-10, Vol.29 (suppl_8) [Periódico revisado por pares]

Oxford University Press

Texto completo disponível

Citações Citado por
9
1496PIntracranial activity of ensartinib in patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC)
1496PIntracranial activity of ensartinib in patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC)
Material Type:
Artigo 		Adicionar ao Meu Espaço

1496PIntracranial activity of ensartinib in patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC)

Wakelee, H ; Reckamp, K L ; Leal, T A ; Patel, S P ; Blumenschein, G ; Shum, E ; Nieva, J ; Oxnard, G ; Sanborn, R E ; Waqar, S ; Zeman, K ; Dukart, G ; Harrow, K ; Liang, C ; Holzhausen, A ; Horn, L

Annals of oncology, 2018-10, Vol.29 (suppl_8) [Periódico revisado por pares]

Oxford University Press

Texto completo disponível

Citações Citado por
10
LBA55Primary efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC)
LBA55Primary efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC)
Material Type:
Artigo 		Adicionar ao Meu Espaço

LBA55Primary efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC)

Kim, E S ; Velcheti, V ; Mekhail, T ; Leal, T A ; Dowell, J E ; Tsai, M L ; Dakhil, C S R ; Stella, P ; Shen, V ; Hu, S ; Paul, S M ; Shames, D S ; Schleifman, E ; Fabrizio, D A ; Yun, C ; Phan, S ; Socinski, M A

Annals of oncology, 2018-10, Vol.29 (suppl_8) [Periódico revisado por pares]

Oxford University Press

Texto completo disponível

Citações Citado por
Resultados 1 2 3 4 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Refinar Meus Resultados

Data de Publicação 

De até
Refinar
  1. Antes de2016  (1)
  2. 2016Até2017  (1)
  3. 2018Até2018  (12)
  4. 2019Até2020  (10)
  5. Após 2020  (15)
  6. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.